*Sussex Eye Hospital, Brighton, United Kingdom; †Brighton and Sussex Medical School, Brighton, United Kingdom; ‡Royal Sussex County Hospital, Brighton, United Kingdom; and §Tongdean Eye Clinic, Hove, United Kingdom.
Cornea. 2014 Sep;33(9):981-4. doi: 10.1097/ICO.0000000000000183.
The aim of this study was to report the use of mitomycin-C (MMC) in the treatment of mucous membrane overgrowth in eyes with osteo-odonto-keratoprosthesis (OOKP).
Records of 4 cases with mucous membrane overgrowth after stage 2 OOKP surgery were reviewed.
All the patients had undergone a mucous membrane trimming procedure followed by MMC application. None of the patients had any episode of recurrence of the mucous membrane overgrowth after a single application of MMC in the follow-up period that ranged from 1 to 11 years.
MMC can successfully arrest mucous membrane overgrowth in OOKP-implanted eyes including refractory cases.
本研究旨在报告在接受骨性牙-角膜-巩膜（OOKP）植入术后，使用丝裂霉素 C（MMC）治疗黏膜过度生长的情况。
回顾了 4 例接受二期 OOKP 手术后出现黏膜过度生长的病例。
所有患者均接受了黏膜修剪术，随后应用 MMC。在随访期间（1 至 11 年），所有患者在单次应用 MMC 后均未出现黏膜过度生长复发。
MMC 可成功抑制 OOKP 植入眼的黏膜过度生长，包括难治性病例。
